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Introduction
Botulinum neurotoxins (BoNTs) are bacterial toxins produced 
by Clostridium botulinum (Schiavo et al., 2000). There are seven 
serotypes, BoNT/A–G, that share similar structures and functions. 
The active form of each toxin molecule is composed of a heavy 
chain ( 100 kD) and a light chain ( 50 kD) connected via a di-
sulfi  de bond (Schiavo et al., 2000; Simpson, 2004). The heavy 
chain mediates the binding and entry of toxins into neurons 
through receptor-mediated endocytosis (Schiavo et al., 2000). 
Once inside neurons, the light chain translocates across the 
endosomal membrane into the cytosol (Schiavo et al., 2000; 
Koriazova and Montal, 2003; Fischer and Montal, 2007), where 
it functions as a protease that cleaves proteins required for exo-
cytosis of synaptic vesicles. BoNT/A and E cleave the peripheral 
membrane protein SNAP-25 (synaptosomal-associated protein of 
25 kD); BoNT/B, D, F, and G cleave the vesicle membrane pro-
tein synaptobrevin (Syb), and BoNT/C cleaves both SNAP-25 
as well as the plasma membrane protein syntaxin (Schiavo et al., 
1992, 1993a,b, 1994; Blasi et al., 1993a,b). SNAP-25, syntaxin, 
and Syb assemble together to form the core of a conserved 
membrane fusion machine that mediates the fusion of synaptic 
vesicles with the plasma membrane (Rothman and Warren, 1994; 
Sudhof, 2004; Jahn and Scheller, 2006). Cleavage of these proteins 
by BoNTs thus inhibits exocytosis of synaptic vesicles. Disrup-
tion of exocytosis at the neuromuscular junction causes fl  accid 
paralysis (botulism), which can lead to death as a result of respi-
ratory failure.
BoNTs are the most toxic substances known (Schiavo 
et al., 2000) and have been classifi  ed as a potential bioterrorism 
threat (Arnon et al., 2001). On the other hand, these toxins are also 
used to treat a variety of human diseases by attenuating over-
active nerve terminals (Montecucco and Molgo, 2005; Verderio 
et al., 2006). The medical applications of BoNTs are not limited to 
motor neurons; these toxins can enter many types of neurons, and 
their use in the central nerve system is being explored (Montecucco 
and Molgo, 2005; Verderio et al., 2006).
A major focus has been to identify the receptors and path-
ways for each BoNT to understand how they recognize and enter 
neurons. The fi  rst reported binding proteins for a BoNT were 
two homologous synaptic vesicle membrane proteins, synapto-
tagmins (Syts) I and II, which bound BoNT/B (Nishiki et al., 
1994, 1996). It was later found that BoNT/G, which shares high 
sequence similarity with BoNT/B, also bound Syts I/II  (Rummel 
et al., 2004a). Several lines of evidence suggest that Syts I/II are 
the receptors for BoNT/B and G: (1) BoNT/B and G bind to the 
luminal region of Syts I/II with high affi  nity (Nishiki et al., 1994, 
1996; Dong et al., 2003; Rummel et al., 2004a; Chai et al., 2006; 
Jin et al., 2006); (2) Syts I/II can mediate the entry of BoNT/B 
into PC12 cells, a neuroendocrine cell line (Dong et al., 2003); 
and (3) peptides containing the toxin-binding site protected motor 
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otulinum neurotoxins (BoNTs) target presynaptic 
nerve terminals by recognizing speciﬁ  c neuronal 
surface receptors. Two homologous synaptic vesicle 
membrane proteins, synaptotagmins (Syts) I and II, bind 
toxins BoNT/B and G. However, a direct demonstration 
that Syts I/II mediate toxin binding and entry into neurons 
is lacking. We report that BoNT/B and G fail to bind and 
enter hippocampal neurons cultured from Syt I knockout 
mice. Wild-type Syts I and II (but not Syt I loss-of-function 
toxin-binding domain mutants) restored binding and entry 
of BoNT/B and G in Syt I–null neurons, thus demon-
strating that Syts I/II are protein receptors for BoNT/B 
and G. Furthermore, mice lacking complex gangliosides 
exhibit reduced sensitivity to BoNT/G, and binding and 
entry of BoNT/A, B, and G into hippocampal neurons 
lacking gangliosides is diminished. These data suggest 
that gangliosides are the shared coreceptor for BoNT/A, 
B, and G, supporting a double-receptor model for these 
three BoNTs for which the protein receptors are known.
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nerve terminals from BoNT/B and G (Dong et al., 2003; Rummel 
et al., 2004a), and mutations within the Syt II–binding region of 
BoNT/B and G reduced the effect of these toxins on motor 
nerve terminals in phrenic nerve preparations (Rummel et al., 
2007). These data support the idea that Syts I/II could serve as 
receptors for BoNT/B and G. However, it has also been reported 
that stimulation of synaptic vesicle exocytosis in cultured hippo-
campal neurons, which exposes Syt I to the cell surface, did not 
increase the functional entry of BoNT/B (Verderio et al., 1999). 
This report raised the interesting possibility that Syt is not the 
receptor for BoNT/B in neurons from the central nerve system 
(Verderio et al., 2006). A direct test of whether Syt I/II expression 
is required for the entry of BoNT/B and G into neurons has 
been lacking.
In addition to protein receptors, a group of membrane glyco-
sphingolipids called gangliosides has been proposed to serve as 
coreceptors for BoNTs (Montecucco, 1986). Complex forms of 
gangliosides called polysialiogangliosides (PSGs) have been 
shown to bind BoNT/A and B (Kitamura et al., 1980; Kozaki 
et al., 1998; Rummel et al., 2004b; Yowler and Schengrund, 2004), 
and mice that lack PSG expression displayed lower sensitivity 
to BoNT/A–C (Kitamura et al., 1999; Tsukamoto et al., 2005). 
It was also reported that phrenic nerve preparations from mice 
lacking PSG are less sensitive to BoNT/G, and mutations within 
the putative ganglioside-binding domain of BoNT/G reduced the 
activity of this toxin in the phrenic nerve preparation (Rummel 
et al., 2007). However, it has not been tested whether ganglio-
sides are required for the toxicity of BoNT/G in vivo. Moreover, 
it has not been directly addressed whether disruption of ganglio-
side synthesis in neurons affects the binding of BoNTs or affects 
other steps in the action of the toxins.
In this paper, we study the binding and entry of BoNTs 
using hippocampal neurons cultured from Syt I knockout (KO) 
mice and ganglioside KO mice as loss-of-function models 
(Geppert et al., 1994; Liu et al., 1999). We found that expression of 
Syts I/II is essential for binding and entry of BoNT/B and G into 
hippocampal neurons, demonstrating that Syts I/II function as 
protein receptors for these two toxins. We further found that 
mice lacking gangliosides are less sensitive to BoNT/G than 
control mice and that gangliosides are important for the binding 
and entry of BoNT/A, B, and G into neurons. Together with 
previous fi  ndings that BoNT/A uses the synaptic vesicle protein 
SV2 as its protein receptor (Dong et al., 2006; Mahrhold et al., 
2006), the data reported here further support a double-receptor 
model for BoNT/A, B, and G, the only three BoNTs for which 
protein receptors have been identifi  ed.
Results
Binding sites for BoNT/B are located in 
synaptic vesicles in hippocampal neurons
Because Syts I/II localize to synaptic vesicles in neurons, where 
they are thought to function as Ca
2+ sensors that regulate exo-
cytosis (Matthew et al., 1981; Brose et al., 1992; Chapman, 2002), 
we fi  rst addressed whether BoNT/B enters neurons via synaptic 
vesicle recycling. To test this, we used cultured hippocampal 
neurons as a model system and drove synaptic vesicle recycling 
by depolarization with high K
+ buffer (56 mM K
+). Cultured 
neurons were exposed to BoNT/B in either control or high K
+ 
buffer. An antibody that recognizes the luminal domain of Syt I 
(Syt IN antibody), which does not interfere with BoNT/B–Syt I 
interactions (Dong et al., 2003), was included in the buffers to 
confi  rm vesicle recycling. As shown in Fig. 1 A, binding of both 
BoNT/B and Syt IN antibody was greatly increased after neurons 
were depolarized with high K
+ buffer, indicating that vesicle 
exocytosis exposes binding sites for BoNT/B. To further con-
fi  rm this fi  nding, we pretreated neurons with tetanus neurotoxin 
(TeNT), which blocks synaptic vesicle exocytosis by cleaving 
Syb (Schiavo et al., 1992). As shown in Fig. 1 B, BoNT/B failed 
to bind neurons that had been pretreated with TeNT, suggesting 
that the binding sites for BoNT/B are located in the lumen of 
synaptic vesicles in hippocampal neurons.
Figure 1.  Binding sites for BoNT/B are exposed upon exocytosis of synaptic vesicles in hippocampal neurons. (A) Rat hippocampal neurons were exposed to 
10 nM BoNT/B and an antibody that recognizes the luminal domain of Syt I (Syt IN antibody; 1:200) in either control buffer (PBS without Ca
2+) or high K
+ 
buffer (PBS with 56 mM KCl and 1 mM Ca
2+) for 5 min. Cells were then ﬁ  xed for immunocytochemistry. Binding of BoNT/B was visualized using an anti-
BoNT/B antibody. Excitatory synapses were labeled using an antibody that recognizes the vesicular glutamate transporter-1 (vGlut-1). The experiments de-
scribed here were performed in at least three independent trials; representative examples of the data are shown. (B) Rat hippocampal neurons were treated 
with 15 nM TeNT for 24 h and were brieﬂ  y exposed to 10 nM BoNT/B for 5 min in high K
+ buffer. Control cells were not treated with TeNT. Immunostaining 
was performed for BoNT/B and Syb II, the substrate of TeNT. Binding of BoNT/B was detected only in neurons that were not treated with TeNT. Bars, 20 μm.ENTRY OF BOTULINUM TOXIN B AND G INTO NEURONS • DONG ET AL. 1513
Hippocampal neurons from Syt I KO mice 
lack both Syts I and II and can actively 
recycle synaptic vesicles
To determine whether Syts I/II are necessary for the binding and 
entry of BoNT/B to neurons, a loss of function model that lacks 
Syts I/II is needed. It is currently thought that most neurons 
  express either Syt I or II, and Syt I is the predominant isoform 
expressed in the hippocampus (Ullrich et al., 1994; Pang et al., 
2006; Fox and Sanes, 2007). Therefore, hippocampal neurons 
from Syt I KO mice would provide a potential loss of function 
model if these neurons do not express Syt II (Geppert et al., 1994). 
To determine this, we fi  rst examined the expression pattern of 
Syts I/II in wild-type (WT) hippocampal neurons. Lysates from 
cultured rat hippocampal neurons were analyzed by Western 
blotting using anti–Syt I and II antibodies. The cytoplasmic do-
mains of Syt (Syt I C2AB and Syt II C2AB), which contain the 
peptide sequences used to raise the antibodies, were included as 
controls. Rat brain detergent extracts were also loaded as addi-
tional controls. Consistent with previous studies (Geppert et al., 
1994; Ullrich et al., 1994), we found that Syt I is abundantly 
expressed in cultured hippocampal neurons (Fig. 2 A, right). 
The Syt II antibody detected 0.3 ng recombinant Syt II under 
these assay conditions, and this antibody detected a protein band 
at 65 kD, corresponding to the molecular weight of Syt II in brain 
detergent extracts. However, Syt II was not detected in lysates 
from cultured hippocampal neurons (Fig. 2 A, left).
We further examined whether there is compensatory ex-
pression of Syt II in hippocampal neurons cultured from Syt I 
KO mice by immunostaining with an anti–Syt II antibody. 
To provide a positive control, we transfected Syt I KO neurons 
with a construct that expresses both Syt II and GFP under two 
separate promoters. We also stained neurons with a synapsin anti-
body to label all synapses. The anti–Syt II antibody specifi  cally 
stained transfected neurons, but no signal was detected in untrans-
fected cells (Fig. 2 B). Thus, hippocampal neurons from Syt I KO 
mice lack both Syt I and Syt II.
Because Syts I and II are essential for triggering the release 
of synaptic vesicles and also play important roles in endocytosis 
of synaptic vesicle components (Chapman, 2002; Pang et al., 
2006), there is a concern that the synaptic vesicle recycling path-
way might be disrupted in neurons lacking Syts I and II. Such de-
fects would block binding and entry of any toxin that used the 
synaptic vesicle cycle to enter neurons. To address this concern, 
we tested whether BoNT/A, which uses the synaptic vesicle 
  protein SV2 as its receptor (Dong et al., 2006), was able to enter 
Syt I KO neurons. The functional entry of BoNT/A into neurons 
was monitored by either staining cells with an antibody that recog-
nizes only the SNAP-25 cleavage product generated by BoNT/A 
(anti–SNAP-25-C; Fig. 3 A; Dong et al., 2006) or by Western blot 
analysis using an anti–SNAP-25 antibody (Fig. 3 B). A similar 
degree of SNAP-25 cleavage was observed in Syt I KO and WT 
neurons. These results suggest that synaptic vesicle recycling is 
preserved in Syt I KO neurons under the conditions we used to 
load toxins (5 min in high K
+ buffer). This conclusion is consis-
tent with previous studies demonstrating that the synaptic vesicle 
cycle remains intact in Syt I KO hippocampal neurons but occurs 
with markedly slower kinetics (Nicholson-Tomishima and Ryan, 
2004; Nishiki and Augustine, 2004). Thus, we conclude that hippo-
campal neurons from Syt I KO mice are a valid loss of function 
model to study the binding and entry of BoNT/B.
Figure 2.  Hippocampal neurons from Syt I KO mice do not express Syt II. (A, left) 30 μg of cell lysates from cultured rat hippocampal neurons (14 DIV) 
and 3.5 μg of rat brain detergent extracts were analyzed by Western blotting using a monoclonal antibody against Syt II. A recombinant Syt II fragment 
containing the antibody epitope was loaded as a positive control (Syt II C2AB). Syt II was detected in brain detergent extracts but not in cultured hippo-
campal neurons. (right) The experiment was performed as described for the left panel except using an anti–Syt I antibody, recombinant Syt I fragment as 
a positive control, and 10 μg of hippocampal neuron lysates. (B) Cultured hippocampal neurons (14 DIV) from Syt I KO mice were transfected with 
a   construct that expresses Syt II and GFP under the control of two separated promoters. The neurons were subsequently immunostained using anti–Syt II 
and   antisynapsin antibodies. The Syt II antibody recognized Syt II in the transfected neuron, which also expresses GFP. Syt II was not detected in untrans-
fected neurons. The experiments described here were performed in at least three independent trials; representative examples of the data are shown. 
Bar, 20 μm.JCB • VOLUME 179 • NUMBER 7 • 2007  1514
BoNT/B fails to bind or enter Syt I KO 
hippocampal neurons
Next, we tested whether the loss of Syt I/II expression in neu-
rons affects the binding of BoNT/B. Hippocampal neurons from 
WT or Syt I KO littermates were exposed to BoNT/B and A in 
high K
+ buffer for 5 min. Neurons were fi  xed, and toxin binding 
was detected by immunofl  uorescence using antibodies against 
BoNT/B and A. SV2 was also stained to mark all synapses. 
As shown in Fig. 3 C, BoNT/B failed to bind Syt I KO neurons. 
A similar degree of BoNT/A binding was observed in Syt I KO 
and WT neurons, thus providing an internal control for synaptic 
vesicle recycling in these neurons (Dong et al., 2006).
We further determined whether the loss of surface binding 
of BoNT/B corresponded to a decrease in functional entry of 
the toxin. Entry of BoNT/B results in the cleavage of Syb II, the 
predominant isoform of Syb in hippocampal neurons; cleavage 
was monitored by the loss of Syb II immunofl  uorescence (Baumert 
et al., 1989; Schiavo et al., 1992). WT and Syt I KO neurons 
were fi  rst exposed to BoNT/B for 5 min in high K
+ buffer 
and were further incubated in the absence of toxin for 24 h. 
As shown in Fig. 3 D, we found that the Syb II immunofl  uorescence 
disappeared from most synapses in WT neurons after exposure 
to BoNT/B. In contrast, the Syb II signal remained intact in Syt I 
KO neurons, indicating that BoNT/B entry into neurons requires 
the expression of Syt I.
Expression of Syt I or II in Syt I KO 
neurons restores binding and 
entry of BoNT/B
To confi  rm that loss of binding and entry of BoNT/B in Syt I 
KO neurons was caused by the absence of Syts I/II, we per-
formed rescue experiments. First, Syt I KO neurons were tran-
siently transfected with plasmids to express either Syt I or II. 
Transfected cells were marked by GFP expression. We found 
that BoNT/B bound to cells that expressed either Syt I (Fig. 4 A, 
top) or Syt II (Fig. 4 A, bottom) but not to untransfected neurons. 
BoNT/A bound to both transfected and untransfected neurons, 
thus serving as a control.
Next, we determined whether the expression of Syt I or II 
in Syt I KO neurons restored the functional entry of BoNT/B. 
Figure 3.  BoNT/B cannot bind or enter Syt I KO hippocampal neurons. (A) Cultured littermate wild-type (WT) and Syt I KO hippocampal neurons were brieﬂ  y 
exposed to 20 nM BoNT/A for 5 min in high K
+ buffer. Neurons were washed, further incubated for 6 h in culture medium, and ﬁ  xed for immunostaining. Cleavage 
of SNAP-25 by BoNT/A was detected using a monoclonal antibody (anti–SNAP-25-C) that recognizes only the cleaved form of SNAP-25. This antibody revealed 
similar levels of immunostaining signals in WT and Syt I KO neurons, indicating that BoNT/A can enter Syt I KO neurons. (B) Experiments were performed as de-
scribed in A except that neurons were harvested and subjected to Western blot analysis. Cleavage of SNAP-25 was detected using an antibody that recognizes 
both intact SNAP-25 as well as the cleavage product (indicated by an asterisk). Syp was assayed as an internal control for equal loading of lysates. (C) Cultured 
littermate WT and Syt I KO hippocampal neurons were simultaneously exposed to 20 nM BoNT/A and 10 nM BoNT/B for 5 min in high K
+ buffer. Neurons 
were washed and ﬁ  xed. Immunostaining was performed using human anti-BoNT/A, rabbit anti-BoNT/B, and mouse anti-SV2 antibodies. (D) WT and Syt I KO 
neurons were exposed to 10 nM BoNT/B for 5 min in high K
+ buffer. Neurons were washed and further incubated for 24 h before ﬁ  xation. Syb II was labeled 
using a monoclonal antibody. Cleavage of Syb II by BoNT/B resulted in the loss of Syb II immunoﬂ  uorescence. All synapses were labeled with an anti-synapsin 
antibody. The experiments described here were performed in at least three independent trials; representative examples of the data are shown. Bars, 20 μm.ENTRY OF BOTULINUM TOXIN B AND G INTO NEURONS • DONG ET AL. 1515
Entry of BoNT/B was determined by monitoring the levels of 
Syb II by immunostaining of neurons (Fig. 4 B) or by Western 
blot analysis of lysates from cultured neurons (Fig. 4 C). Syt I 
KO neurons were infected with lentiviruses that expressed ei-
ther Syt I or II. The effi  ciency of infection was usually >90%. 
Infected neurons were exposed to BoNT/B for 5 min and were 
further incubated for 24 h. We found that the level of Syb II was 
greatly reduced by BoNT/B in neurons that expressed either 
Syt I or II virus (Fig. 4, B and C), demonstrating that BoNT/B 
entered infected neurons and cleaved Syb II.
BoNT/G enters neurons via recycling 
synaptic vesicles
Syts I/II have also been suggested to serve as the receptors 
for BoNT/G, which is closely related to BoNT/B (Rummel 
et al., 2004a). Data supporting this idea include the following: 
Figure 4.  Expression of Syt I or II restores the binding and entry of BoNT/B into Syt I KO hippocampal neurons. (A) Syt I KO neurons were transfected with 
either Syt I or II and exposed to BoNT/A and BoNT/B as described in Fig. 3 A. Immunostaining was performed using anti-BoNT/A and B antibodies. 
The constructs that express Syt I or II also express GFP under the control of a separate promoter. BoNT/B bound only to neurons transfected with Syt I or II. 
BoNT/A bound to all synapses, thus serving as a control. (B) Syt I KO neurons were infected with lentiviruses that express either Syt I or II. Neurons were 
exposed to 10 nM BoNT/B for 5 min in high K
+ buffer and were further incubated for 24 h before ﬁ  xation. Immunostaining was performed as described 
in Fig. 3 A. GFP signals indicate infected neurons. BoNT/B failed to enter Syt I KO neurons but readily entered Syt I KO neurons that expressed either 
Syt I or II, as indicated by the loss of Syb II in these neurons. (C) Experiments were performed as described in B except that neurons were harvested, and 
cell lysates were subjected to Western blot analysis using antibodies against Syt I, Syb II, and Syp. The experiments described here were performed in at 
least three independent trials; representative examples of the data are shown. Bars, 20 μm.JCB • VOLUME 179 • NUMBER 7 • 2007  1516
(1) BoNT/G binds directly to the luminal domain of Syts I and II 
(Rummel et al., 2004a); (2) recombinant Syt luminal fragments 
can reduce the toxicity of BoNT/G at motor nerve terminals 
(Rummel et al., 2004a); and (3) mutations within the putative 
Syt-binding domain of BoNT/G reduced the activity of BoNT/G 
at motor nerve terminals (Rummel et al., 2007). Although these 
experiments are consistent with a model in which Syts I/II are 
the receptors for BoNT/G, direct experiments that address 
whether Syts I/II are required for functional entry of BoNT/G 
into neurons have not been reported.
To study whether Syts I/II mediate the entry of BoNT/G, 
we fi  rst sought to determine whether BoNT/G enters neurons 
via recycling synaptic vesicles. Because an anti-BoNT/G anti-
body is not currently available, we monitored the binding of an 
epitope-tagged receptor-binding domain of this toxin to neurons. 
This receptor-binding domain of BoNT/G was purifi  ed as a 
FLAG-tagged recombinant protein (BoNT/G-HCR;  50 kD; see 
Materials and methods for details). This BoNT/G-HCR fragment 
was capable of antagonizing the binding of BoNT/G to its receptor 
on neurons because Syb II, the substrate protein of BoNT/G 
Figure 5.  The receptor-binding domain of BoNT/G (BoNT/G-HCR) binds to hippocampal neurons in an activity-dependent manner and blocks binding and 
entry of BoNT/B and G. (A) Cultured rat hippocampal neurons were exposed to 10 nM BoNT/G with or without high concentrations of BoNT/G-HCR (600 nM) 
for 5 min in high K
+ buffer. Cells were further incubated for 24 h before ﬁ  xation. Immunostaining was performed using anti–Syb II and anti-synapsin anti-
bodies. (B) Experiments were performed as described in A except that cells were harvested and subjected to Western blot analysis to detect Syp and Syb II. 
The presence of BoNT/G-HCR protected Syb II from cleavage by BoNT/G, presumably by competing with the binding of BoNT/G to neurons. (C) Rat 
hippocampal neurons were exposed to both 20 nM BoNT/A and 100 nM BoNT/G-HCR for 5 min in either control buffer or high K
+ buffer. Cells were washed, 
and immunostaining was performed using anti-BoNT/A antibody and anti-FLAG antibody, which recognizes the FLAG tag at the N terminus of BoNT/G-
HCR. An anti–Syt I antibody was used to label all synapses. Stimulation of neurons with high K
+ buffer increased the binding of BoNT/G-HCR. 
BoNT/A served as a control. (D) Rat hippocampal neurons were exposed to 20 nM BoNT/A and 10 nM BoNT/B with (left) or without (right) 400 nM 
BoNT/G-HCR for 5 min in high K
+ buffer. Cells were washed and ﬁ  xed. Immunostaining was performed using anti-BoNT/A, anti-BoNT/B, and anti-FLAG 
antibodies. High concentrations of BoNT/G-HCR did not affect the binding of BoNT/A but blocked the binding of BoNT/B to neurons. The experiments 
described here were performed in at least three independent trials; representative examples of the data are shown. Bars, 20 μm.ENTRY OF BOTULINUM TOXIN B AND G INTO NEURONS • DONG ET AL. 1517
(Schiavo et al., 1994), was protected from cleavage by BoNT/G 
in the presence of high concentrations of BoNT/G-HCR (Fig. 5, 
A and B). Using this fragment, we found that stimulation 
of neurons with high K
+ signifi  cantly increased the binding 
of BoNT/G-HCR, suggesting that the binding site for BoNT/G 
is localized to synaptic vesicles (Fig. 5 C). Furthermore, we 
found that excess levels of BoNT/G-HCR blocked the binding 
of BoNT/B to neurons (Fig. 5 D). This competition is specifi  c 
to BoNT/B because the binding of BoNT/A was not affected 
(Fig. 5 D). These results suggest that BoNT/G recognizes the same 
binding site on neurons as BoNT/B.
Binding and entry of BoNT/G into neurons 
requires Syts I/II
Next, we determined whether the lack of Syt I and II expression 
in neurons results in diminished binding of BoNT/G. As shown 
in Fig. 6 A, BoNT/G-HCR failed to bind Syt I KO neurons. This 
loss of binding was restored upon the expression of either Syt I 
or II (Fig. 6 B). We further tested whether loss of Syts I/II blocks 
the functional entry of BoNT/G into neurons. WT and Syt I KO 
neurons were exposed to BoNT/G for 5 min in high K
+ buffer 
and were further incubated for 24 h. The level of Syb II was 
monitored by either immunostaining (Fig. 6 C) or Western blot-
ting (Fig. 6 D). Although Syb II disappeared from most syn-
apses in WT neurons after exposure to BoNT/G, the level of 
Syb II in Syt I KO neurons remained the same as in neurons that 
had not been exposed to BoNT/G, demonstrating that BoNT/G 
failed to enter Syt I KO neurons. Furthermore, entry of BoNT/G 
was rescued by expressing either Syt I or II in Syt I KO neurons 
(Fig. 6, C and D). Together, these results provide direct evidence 
that Syts I and II are the protein receptors that mediate the binding 
and entry of BoNT/G into neurons.
Syt I mutants harboring loss-of-function 
mutations within the BoNT/B–G-binding 
domain failed to rescue toxin binding in 
Syt I KO neurons
The crystal structure of BoNT/B bound to the toxin-binding site 
of Syt II was recently reported. A hydrophobic groove within the 
C-terminal domain of BoNT/B interacts with a short segment 
within the luminal domain of Syt II (Chai et al., 2006; Jin et al., 
2006). This hydrophobic groove is conserved in all subtypes of 
BoNT/B as well as in BoNT/G. The structure also revealed that 
only residues 45–59 of Syt II interact with BoNT/B. Within this 
segment, F47, F54, F55, and E57 of Syt II appear to form critical 
contacts with BoNT/B (Chai et al., 2006; Jin et al., 2006). These 
structural details enabled us to perform targeted mutagenesis on 
Syts I/II to selectively disrupt its toxin-binding activity.
To address the concern that mutagenesis within the toxin-
binding site may alter the membrane topology or targeting of 
Syt, we chose to focus this analysis on Syt I instead of Syt II. 
This is because exposure of the Syt I luminal domain to the cell 
surface during synaptic vesicle recycling can be conveniently 
monitored using an antibody that recognizes an epitope in the 
N terminus of the luminal domain (Syt IN antibody; Fig. 1 A). 
This provides a simple readout to confi  rm the correct targeting 
of mutant forms of Syt I.
As shown in Fig. 7 A, two mutants were designed: a dele-
tion mutant that lacked a critical toxin-binding segment (∆39–49 
in Syt I, corresponding to residues 47–57 of Syt II) and a triple 
mutant that harbored substitutions of three key residues (F46A, 
M47A, and E49K of Syt I, corresponding to residues F54, F55, 
and E57 of Syt II). WT and mutant forms of Syt I were ex-
pressed in Syt I KO neurons and exposed to both BoNT/B and 
Syt IN antibody. The luminal domains of WT and mutant forms 
of Syt I were all exposed to the surface of cells after stimulation 
with high K
+, as indicated by the binding of Syt IN antibody 
(Fig. 7 B). However, binding of BoNT/B was observed only on 
neurons that expressed WT Syt I but not with neurons that ex-
pressed the deletion or triple mutant protein (Fig. 7 B). The same 
results were observed for BoNT/G-HCR (Fig. 7 C). These results 
demonstrate that BoNT/B and G bind neurons via direct inter-
actions with the luminal domain of Syt I and also validate the 
crystal structure of the BoNT/B–Syt II complex (which was ob-
tained in the absence of the ganglioside coreceptor using a Syt II 
fragment that lacked the transmembrane domain of the protein).
Gangliosides are essential for the binding 
of BoNT/A, B, and G to neurons
In addition to protein receptors, it has been proposed that 
gangliosides may serve as coreceptors for BoNTs (Montecucco, 
1986). A role for gangliosides in vivo has been previously dem-
onstrated for BoNT/A and B by the fi  nding that mice lacking 
complex gangliosides (PSGs) are less sensitive to these toxins 
(Kitamura et al., 1999). However, it has not been determined 
whether gangliosides are required for the toxicity of BoNT/G 
in vivo. Thus, we extended a previous study to assess whether gan-
gliosides are necessary for the toxicity of BoNT/G in vivo using 
a KO mouse line that lacks PSGs as a result of the disruption of 
GM2/GD2 synthase (GalNac-T
−/−, denoted as ganglioside KO 
hereafter), an enzyme required to synthesize complex ganglio-
sides (Liu et al., 1999). The sensitivity of ganglioside KO mice 
to BoNT/G was compared with WT mice using an established 
rapid time to death assay (Dong et al., 2003). Identical amounts 
of BoNT/G were injected into WT and ganglioside KO litter-
mate mice, and the survival time (time to death) of each mouse 
was determined. The survival time was converted to units of 
LD50 as previously described (Dong et al., 2003). As shown in 
Fig. 8 A, ganglioside KO mice survived a mean of 132 min, 
whereas WT mice survived only 51 min. The difference in the 
survival time corresponds to a 20-fold difference in the apparent 
LD50 value (i.e., although the same amount of toxin was injected 
into WT and ganglioside KO mice, the toxicity displayed in 
ganglioside KO mice is 20 times lower than that of WT mice). 
These results indicate that gangliosides are important for the 
toxicity of BoNT/G in vivo.
The data from the in vivo experiments demonstrate the 
physiological importance of PSGs for the toxicity of BoNT/A, 
B, and G. However, whether this reduction in toxicity is caused 
by a decrease in toxin binding to neurons or by changes in 
other steps in the action of these toxins has not been addressed. 
Therefore, we examined the binding of BoNT/A and B and 
BoNT/G-HCR to hippocampal neurons cultured from ganglioside 
KO and WT mice. As shown in Fig. 8 B, BoNT/A and B failed JCB • VOLUME 179 • NUMBER 7 • 2007  1518
to bind neurons from ganglioside KO mice. Binding of BoNT/G-
HCR to the ganglioside KO neurons was greatly diminished but 
was not completely abolished. The loss of binding in these 
  experiments was caused by the absence of gangliosides because 
binding was restored by loading the KO neurons with exogenous 
gangliosides (Fig. 8 B). These data suggest that gangliosides are 
coreceptors that are required for the binding of BoNT/A, B, and 
G to neurons.
We further assayed whether the loss of binding in the afore-
mentioned experiments corresponded to a decrease in functional 
entry of the toxins. WT neurons, ganglioside KO neurons, and 
ganglioside KO neurons that had been loaded with exogenous 
gangliosides were exposed to either BoNT/A and B simultane-
ously (Fig. 8 C, left) or to BoNT/G (Fig. 8 C, right) for 5 min in 
high K
+ buffer; neurons were then further incubated in the absence 
of toxin for 24 h. Cell lysates were analyzed by Western blotting. 
Figure 6.  Expression of Syt I or II restores the binding and entry of BoNT/G into Syt I KO neurons. (A) WT and Syt I KO neurons were exposed to 100 nM 
BoNT/G-HCR and 20 nM BoNT/A for 5 min in high K
+ buffer. Immunostaining was performed using anti-BoNT/A and anti-FLAG antibodies. BoNT/G-HCR 
failed to bind Syt I KO neurons. BoNT/A served as a control. (B) Syt I KO neurons were transfected with either Syt I or II. Cells were then exposed to BoNT/A 
and BoNT/G-HCR, and immunostaining was conducted as described in A. Transfected neurons were visualized by GFP expression. BoNT/G-HCR bound 
only to neurons that expressed either Syt I or II. (C) WT neurons, Syt I KO neurons, and Syt I KO neurons infected with Syt I or II viruses were exposed 
to 30 nM BoNT/G for 5 min in high K
+ buffer. Neurons were washed and further incubated for 24 h before ﬁ  xation, and immunostaining was performed 
using anti–Syb II and antisynapsin antibodies. Cleavage of Syb II by BoNT/G resulted in reduced immunostaining signals for Syb II. The levels of Syb II in 
Syt I KO neurons remained the same as in neurons that were not exposed to BoNT/G, indicating that BoNT/G failed to enter Syt I KO neurons. Expression 
of Syt I or II restored the entry of BoNT/G. (D) Experiments were performed as described in C except that neurons were harvested and subjected to Western 
blot analysis to detect Syt I, Syb II, and Syp. The experiments described here were performed in at least three independent trials; representative examples 
of the data are shown. Bars, 20 μm.ENTRY OF BOTULINUM TOXIN B AND G INTO NEURONS • DONG ET AL. 1519
SNAP-25 and Syb II were protected from BoNT/A and BoNT/B, 
respectively, in ganglioside KO neurons, whereas they were 
cleaved in KO neurons that had been loaded with exogenous 
gangliosides (Fig. 8 C, left). We observed only partial protec-
tion of Syb II from BoNT/G in ganglioside KO neurons. Together 
with the observation that there is a low level of binding of 
BoNT/G-HCR to ganglioside KO neurons (Fig. 8 B, right), these 
data suggest that BoNT/G is less dependent on the presence of 
gangliosides than BoNT/A and B in hippocampal neurons under 
our experimental conditions.
Discussion
Femtomolar levels of BoNTs in the bloodstream of humans and 
other animals can cause paralysis. The extreme effi  cacy of BoNTs 
in vivo is caused not only by their enzymatic activity (cleavage 
of SNARE proteins) but also involves their ability to selectively 
target neurons. Thus, a major focus is to identify the receptors 
and entry pathways for each BoNT. In this study, we performed 
experiments to address the questions of whether Syts I and II 
function as the protein receptors for BoNT/B and G in neurons 
and whether gangliosides are required for the binding of BoNT/A, 
B, and G to neurons.
To address the role of Syts I/II, we used cultured hippo-
campal neurons from Syt I KO mice as our model system. 
We fi rst observed that BoNT/B and G are unable to bind or enter 
Syt I KO hippocampal neurons, which lack both Syts I and II; 
binding and entry was restored by expressing Syt I or II. The lack 
of binding and entry of BoNT/B and G using Syt I KO neurons 
was not the result of impaired synaptic vesicle recycling caused 
Figure 7.  Mutations in the toxin-binding site of Syt I disrupt interactions with BoNT/B and G on the surface of hippocampal neurons. (A) Schematic dia-
gram of the Syt I deletion mutation and triple point mutation. The image was generated using the crystal structure of the cytoplasmic domain of Syt III (Sutton 
et al., 1999); the remaining regions were added with a drawing program. Asterisks indicate the three residues that are mutated in Syt I. Bold letters indicate 
amino acids that were used to replace the original amino acids in Syt I triple mutation. (B) WT, deletion mutant, and the triple mutant version of Syt I were 
expressed in Syt I KO neurons, and neurons were exposed to both BoNT/B and Syt IN antibody for 5 min in high K
+ buffer. Cells were ﬁ  xed and imaged. 
Binding of BoNT/B was visualized using an anti-BoNT/B antibody. The Syt IN antibody bound to neurons expressing WT, deletion, or triple mutant versions 
of Syt I; BoNT/B bound only to neurons that expressed WT Syt I. (C) Experiments were performed as described in B except that neurons were exposed to 
BoNT/G-HCR. Binding of BoNT/G-HCR was observed only for neurons that expressed WT Syt I. The experiments described here were performed in at 
least three independent trials; representative examples of the data are shown. Bars, 20 μm.JCB • VOLUME 179 • NUMBER 7 • 2007  1520
by the loss of Syt I because BoNT/A, which also enters neurons 
via recycling synaptic vesicles, effi  ciently bound and entered these 
neurons. To further explore this question, we designed two Syt I 
mutants that harbored loss of function mutations within the 
toxin-binding site (a deletion mutant and a triple mutant) based 
on the crystal structure of the BoNT/B–Syt II complex. Once 
expressed in Syt I KO neurons, these mutant forms of Syt main-
tained the correct membrane topology, as indicated by the binding 
of Syt IN antibody to their luminal domain. However, both mu-
tants failed to rescue the binding of BoNT/B and G. These data 
further establish Syt as a protein receptor for BoNT/B and G 
and also validate the physiological relevance of the crystal struc-
ture of the BoNT/B–Syt II complex. These experiments pro-
vide the fi  rst cell-based data showing that specifi  c mutations 
within the toxin-binding site of Syt render neurons resistant 
to BoNT/B and G.
To address the role of gangliosides in the action of the 
BoNTs, we used ganglioside KO mice as a model system. We 
found that ganglioside KO mice displayed a lower sensitivity to 
BoNT/G in vivo, as reported previously for BoNT/A and B 
(Kitamura et al., 1999), indicating that gangliosides are important 
for the toxicity of BoNT/G in intact animals. Moreover, we demon-
strate that binding and entry of BoNT/A, B, and G was reduced 
using neurons that lacked gangliosides. This defect was caused 
by the lack of gangliosides because binding and entry was res-
cued by adding back exogenous gangliosides. Together with 
the previous fi  nding that SV2 is the protein receptor for BoNT/A 
(Dong et al., 2006), the current data support a double-receptor 
Figure 8.  Binding and entry of BoNT/A, B, and G is reduced in neurons lacking gangliosides. (A) 5-wk-old littermate WT and ganglioside KO mice were 
injected with the same amount of BoNT/G. The survival time of each mouse (time to death, given in minutes) was determined, and the apparent lethal dose 
(LD50) of toxin was calculated based on their survival time as described previously (Dong et al., 2003). Data from ﬁ  ve representative pairs are shown. 
(B) Cultured littermate WT and ganglioside KO neurons were exposed to 20 nM BoNT/A, 10 nM BoNT/B, or 100 nM BoNT/G-HCR (right) for 5 min in 
high K
+ buffer. Ganglioside KO neurons preloaded with exogenous gangliosides (250 mg/ml ganglioside mixture for 12 h) were also tested in parallel. 
Cells were washed and ﬁ  xed. Immunostaining was performed using antibodies against BoNT/A, BoNT/B, and FLAG tag. vGlut-1 was also labeled to visual-
ize synapses. (C) Cultured WT and ganglioside KO neurons were exposed to 5 nM BoNT/A and 10 nM BoNT/B simultaneously (left) or to 30 nM BoNT/G 
alone (right) for 5 min in high K
+ buffer. Ganglioside KO neurons preloaded with exogenous gangliosides were also tested in parallel. Neurons were 
washed and incubated for 24 h. Cells were harvested and subjected to Western blot analysis. Syt I was assayed as an internal control for equal loading of 
lysates. The experiments described here were performed in at least three independent trials; representative examples of the data are shown. Bar, 20 μm.ENTRY OF BOTULINUM TOXIN B AND G INTO NEURONS • DONG ET AL. 1521
model for BoNT/A, B, and G, which predicted that the recep-
tors for BoNTs are composed of both gangliosides and proteins 
(Montecucco, 1986).
In contrast to the loss of binding of BoNT/A and B to 
hippocampal neurons cultured from ganglioside KO mice, a low 
level of BoNT/G binding activity persisted. This low level of 
BoNT/G binding was confi  rmed by the fact that there was only 
partial protection of Syb II cleavage by BoNT/G in neurons that 
lacked gangliosides. These fi  ndings suggest that BoNT/G is less 
dependent on gangliosides under our experimental conditions, 
although the presence of gangliosides clearly enhances the bind-
ing and entry of BoNT/G into hippocampal neurons.
It was recently reported that protease treatment or boiling 
of purifi  ed rat brain synaptosomes did not affect the binding of 
two other members of the BoNT family, BoNT/C and D, sug-
gesting that these toxins might not have proteinaceous receptors 
(Tsukamoto et al., 2005). Furthermore, although gangliosides 
are essential for the entry of BoNT/C, they are not required for 
the entry of BoNT/D in vivo (Tsukamoto et al., 2005). Thus, the 
double-receptor model may not apply to all BoNTs.
Materials and methods
Antibodies, materials, cell lines, and mouse lines
Monoclonal antibodies directed against Syb II (CI 69.1), Syt I (α–Syt IN, 
CI 604.4; α–Syt I C2AB, CI 41.1), SV2 (pan-SV2), synaptophysin (Syp; 
CI 7.2), and SNAP-25 (CI 71.2) were provided by R. Jahn (Max-Planck-
  Institute for Biophysical Chemistry, Gottingen, Germany). A human anti-
BoNT/A (RAZ-1) was provided by J. Lou and J. Marks (University of 
California, San Francisco, San Francisco, CA). Rabbit anti-BoNT/B anti-
bodies were generated using puriﬁ  ed neurotoxin. The following antibodies 
were purchased from the indicated companies: mouse monoclonal anti–
Syt II (BD Biosciences), mouse monoclonal anti–SNAP-25-C (Research & 
Diagnostic Antibodies), rabbit polyclonal antisynapsin and guinea pig 
anti–vesicular glutamate transporter 1 (Chemicon), chicken polyclonal anti-
GFP (Abcam), and mouse monoclonal anti-FLAG (M2; Sigma-Aldrich). Bovine 
brain gangliosides were obtained from Matreya LLC. BoNT/G was ob-
tained from Metabiologics. Rat brain detergent extracts were prepared 
from crude synaptosomes using 1% Triton X-100 as described previously 
(Lewis et al., 2001).
A Syt I KO mouse line has been described previously (Geppert et al., 
1994) and was obtained from The Jackson Laboratory. Ganglioside KO 
mice lack the gene encoding GM2/GD2 synthase (gene symbol Galgt1). 
This mouse line was described previously (Liu et al., 1999) and was   obtained 
from the Consortium for Functional Glycomics. Genotypes were determined 
by PCR.
cDNA and expression constructs
The following cDNA were provided by the indicated groups. Rat Syt I was 
provided by T.C. Sudhof (University of Texas Southwestern Medical Center, 
Dallas, TX), and mouse Syt II was provided by M. Fukuda (RIKEN Institute 
of Physical and Chemical Research, Ibaraki, Japan). Syt I C2AB and Syt II 
C2AB were described previously (Hui et al., 2005). To express Syts I/II in 
neurons, full-length Syts I and II were subcloned into the Lox-Syn-Syn lentivirus 
vector, which has been described previously (Dong et al., 2006). This vec-
tor contains two separate neuronal-speciﬁ  c promoters (synapsin promoter). 
One promoter controls the expression of Syt, and the other promoter controls 
the expression of GFP to detect transfected cells.
BoNT/G-HCR recombinant protein was provided by J. Barbieri 
(Medical College of Wisconsin, Milwaukee, WI). This fragment corresponds 
to residues 863–1,297 of BoNT/G with a His6 tag and 3xFLAG tag at the 
N terminus. Vector construction and protein puriﬁ  cation procedures were 
performed as described previously (Baldwin and Barbieri, 2007).
Neuronal cell cultures, transfection, cell lysates, viral infection, and 
loading gangliosides
Hippocampal neurons were prepared from embryonic day 18–19 rats. 
Cultured Syt I KO and ganglioside KO hippocampal neurons were   prepared 
from postnatal day 1 mice. Neurons were plated on 12-mm poly-D-lysine–
coated glass coverslips at a density of 50,000/cm
2 and cultured in neuro-
basal medium supplemented with 2% B-27 and 2 mM glutamax. Transfections 
were performed on neurons at 5 d in vitro (DIV) using Lipofectamine 2000 
(Invitrogen) and were analyzed at 14 DIV.
Lysates from cultured neurons (14 DIV) were prepared by ﬁ  rst wash-
ing cells with PBS. Then, 100 μl of lysis buffer (PBS with 1% Triton X-100, 
0.05% SDS, and protease cocktails) was added per coverslip. Lentiviral 
particles were generated by cotransfecting HEK293 cells with the virus 
packaging vectors (vesicular stomatitis virus G glycoprotein and ∆8.9) and 
Syt I or II in Lox-Syn-Syn lentivirus vector. Viruses were added to neurons at 
5 DIV, and these neurons were analyzed at 14 DIV. To load cells with ex-
ogenous gangliosides, ganglioside KO neurons were incubated in media 
plus 250 μg/ml gangliosides for 12 h.
Binding of BoNTs to hippocampal neurons and immunocytochemistry
The buffers used in Fig. 1 A were control buffer (140 mM NaCl, 3 mM KCl, 
1.5 mM KH2PO4, 8 mM Na2HPO4, and 0.5 mM MgCl2) and high K
+ 
(same as control buffer but adjusted to 56 mM KCl and 87 mM NaCl and 
contains 1 mM CaCl2). Unless speciﬁ  ed in the text, hippocampal neurons 
were generally exposed to toxins in high K
+ buffer for 5 min. All images 
were collected using a confocal microscope (FV1000; Olympus) with a 
60× NA 1.10 water immersion objective (Olympus) at 25°C. Immunoﬂ  uor-
escence was visualized using secondary antibodies conjugated with Cy2, 
Cy3 (Jackson ImmunoResearch Laboratories), or AlexaFluor647 (Invitrogen). 
Images were acquired using Fluoview software version 1.6 (Olympus). 
The only image parameters that were adjusted were the brightness and 
contrast, which were processed using Photoshop version CS (Adobe).
Rapid BoNT toxicity assay in mice
BoNT/G effective toxicity in mice was estimated using the intravenous 
method described previously (Dong et al., 2003). In brief, each mouse was 
injected intravenously (lateral tail vein) with 0.1 ml BoNT/G (10 μg/ml), and 
their time to death was determined. The time to death values were converted 
to intraperitoneal LD50/milliliter using a standard curve (Dong et al., 2003).
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